Inhaled corticosteroid use to prevent severe vaso-occlusive episode recurrence in children between 1 and 4 years of age with sickle cell disease: a multicenter feasibility trial.
Leah Vance Utset, Zalaya Ivy, Shaina M Willen, Mark Rodeghier, Amanda Watt, Leann Schilling, Chantel L Jenkins, Stefanie Pepper, Barbara Speller-Brown, Deepika S Darbari and 3 more
Open access · bronzeAbstract readClinical TrialLetterMulticenter Study
Trial report in American journal of hematology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 7 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
13 authors at 5 institutions in 1 country.
Leah Vance UtsetVanderbilt University School of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.ORCID 0000-0001-8734-7952
Zalaya IvySchool of Medicine, , Meharry Medical College, Nashville, Tennessee.
Shaina M WillenDivision of Hematology/Oncology, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee.ORCID 0000-0002-6691-816X
Mark RodeghierIndependent Statistician, Chicago, Illinois.
Amanda WattAflac Cancer and Blood Disorder Center, Children's Healthcare of Atlanta, Atlanta, Georgia.
Leann SchillingAflac Cancer and Blood Disorder Center, Children's Healthcare of Atlanta, Atlanta, Georgia.
Chantel L JenkinsDepartment of Pediatrics, Children's National Health System, Washington, District of Columbia.
Stefanie PepperDepartment of Pediatrics, University of Mississippi Medical Center, Jackson, Mississippi.
Barbara Speller-BrownDepartment of Pediatrics, Children's National Health System, Washington, District of Columbia.
Deepika S DarbariDepartment of Pediatrics, Children's National Health System, Washington, District of Columbia.
Suvankar MajumdarDepartment of Pediatrics, University of Mississippi Medical Center, Jackson, Mississippi.
Olufolake AdisaAflac Cancer and Blood Disorder Center, Children's Healthcare of Atlanta, Atlanta, Georgia.
Michael R DeBaunDivision of Hematology/Oncology, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee.ORCID 0000-0002-0574-1604
Aflac (United States) · USChildren's National · USVanderbilt University Medical Center · USJackson Memorial Hospital · USMeharry Medical College · US
Funding
Cellular and Molecular Mechanisms of Acute Lung Injury in Sickle Cell DiseaseU01HL117721 · NHLBI · EMORY UNIVERSITY · PI DEBAUN, MICHAEL R., JOINER, CLINTON H · 2013 to 2017
$9.4M
Clinical and Translational Training Program in Pulmonary MedicineT32HL087738 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Lorraine B Ware · 2007 to 2026
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Inhaled corticosteroid use to prevent severe vaso-occlusive episode recurrence in children between 1 and 4 years of age with sickle cell disease: a multicenter feasibility trial. · full record | OpenQuestion